ImmunityBio Surges 14.55% Pre-ASCO; Anktiva Sales Up 700%
ImmunityBio shares surged 14.55% on Monday as investors positioned ahead of the ASCO Genitourinary Cancers Symposium scheduled Feb. 26–28 in San Francisco. Earlier this year the company reported a 700% sales increase for its Anktiva therapy and secured approval to begin lung cancer treatment sales in Saudi Arabia.
1. Share Price Rally
On Monday ImmunityBio shares jumped 14.55% as investors loaded positions ahead of its presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium set for February 26–28 in San Francisco.
2. ASCO Participation Details
The three-day symposium will showcase the latest advances in prostate, bladder, kidney and testicular cancer research, with market watchers looking for updates on ImmunityBio’s immune-oncology pipeline.
3. Anktiva Growth and Expansion
Earlier this year the company achieved a 700% increase in Anktiva therapy sales and announced plans to launch the drug, in combination with an immune checkpoint inhibitor, for lung cancer patients in Saudi Arabia following regulatory approval.